STOCK TITAN
  1. Home
  2. News
  3. CRSP

CRISPR Therapeutics AG - CRSP STOCK NEWS

Welcome to our dedicated news page for CRISPR Therapeutics (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRISPR Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRISPR Therapeutics's position in the market.

News
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.3%
Tags
conferences
-
News
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics (CRSP) announced the FDA approval of CASGEVY™, a CRISPR-based gene-editing therapy, for the treatment of sickle cell disease in patients 12 years and older. This marks the first-ever approval of a CRISPR-based gene-editing therapy in the U.S. and offers a one-time treatment option for approximately 16,000 eligible patients with severe sickle cell disease. The therapy has the potential to eliminate severe vaso-occlusive crises and hospitalizations caused by the disease, providing a functional cure for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
fda approval
-
News
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) provided an update on its immuno-oncology pipeline, focusing on next-generation CAR T product candidates CTX112™ targeting CD19 and CTX131™ targeting CD70. Preliminary data from ongoing clinical trials suggest that these candidates may improve upon the clinical profile of first-generation candidates CTX110 and CTX130, with increased CAR T cell expansion and functional persistence. The Company is transitioning patients treated with CTX110 and CTX130 to long-term follow-up and plans to expand trials of CTX112 into autoimmune disease and CTX131 into hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
News
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced the first regulatory authorization of a CRISPR-based gene-editing therapy in the world. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The therapy is indicated for eligible patients 12 years of age and older. CASGEVY has been authorized for the treatment of patients with recurrent vaso-occlusive crises or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. The safety profile of patients treated with CASGEVY in clinical trials is generally consistent with myeloablative conditioning with busulfan and hematopoietic stem cell transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
-
News
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
CRISPR Therapeutics completes Advisory Committee meeting for exa-cel for severe sickle cell disease (SCD) and assigns Prescription Drug User Fee Act (PDUFA) target action dates for SCD and transfusion-dependent beta thalassemia (TDT). Ongoing clinical trials for CAR T product candidates targeting B-cell malignancies, T cell malignancies and solid tumors. Also, clinical trials ongoing for VCTX211 for Type 1 Diabetes and CTX310 targeting angiopoietin-related protein 3 (ANGPTL3).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.57%
Tags
earnings
-
News
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
Rhea-AI Summary
CRISPR Therapeutics announces preclinical data from investigational programs for cardiovascular disease treatment. CTX310™ shows durable reductions in ANGPTL3 protein and triglyceride levels in non-human primates after a single dose. CTX320™ shows durable reductions in lipoprotein(a) levels in non-human primates after a single dose. Clinical trial initiated for CTX310™, targeting ANGPTL3. CTX320™ targeting Lp(a) is on track to enter the clinic in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
clinical trial
News
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease
Rhea-AI Summary
CRISPR Therapeutics announced the completion of the FDA's advisory committee meeting for exa-cel, a potential therapy for severe sickle cell disease (SCD). The PDUFA target action date for SCD is December 8, 2023. If approved, exa-cel could be the first genetic therapy available to approximately 20,000 people with severe SCD in the U.S. The BLA for transfusion-dependent beta-thalassemia (TDT) has a PDUFA date of March 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.38%
Tags
none
-
News
CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)
Rhea-AI Summary
CRISPR Therapeutics (Nasdaq: CRSP) announces trading halt as FDA reviews Biologics License Application for exagamglogene autotemcel (exa-cel) for sickle cell disease treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Rhea-AI Summary
CRISPR Therapeutics announces poster presentations of preclinical data at SITC 38th Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
conferences
News
CRISPR Therapeutics Announces Leadership Transition
Rhea-AI Summary
CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
management
Stock CRSP logo
CRISPR Therapeutics AG

Nasdaq:CRSP

CRSP Rankings

#1251 Ranked by Market Cap
#3655 Ranked by Stock Gains
N/A Ranked by Dividends

CRSP Stock Data

5.15B
78.84M
1.35%
65.69%
18.38%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Switzerland
Zug

About CRSP

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.